Latest Azole antifungals Effective Treatment options for Superficial Fungal Infections and onychomycosis

They noted that none of the new azoles is US FDA approved for onychomycosis treatment; however, an increasing number of studies have evaluated these agents.

Key findings of the study:

♦ Upon analysis, the researchers found that the efficacies (complete cure and mycologic cure) of the antifungal agents for dermatophyte great toenail onychomycosis treatment are

• Terbinafine (250 mg/day for 12 weeks, complete cure: 38.0%; mycological cure: 70.0%) and
• Itraconazole (200 mg/day for 12 weeks, complete cure: 14%; mycological cure: 54.0%).

♦ They also found that the complete cure rate and mycological cure rate were superior for all the alternative agents with ravuconazole (59.4%, 82.0%; 100 mg/day for 12 weeks) showing the most promising results.

The authors concluded, "In the course of treatment of onychomycosis and dermatomycoses, resistant to terbinafine and itraconazole (on-label) and flucanazole (Off-label) is being increasingly reported. In such scenarios, new azoles such as posaconazole, fosravuconazole, voriconazole, and oteseconazole are being considered for the treatment of superficial fungal infection."

For further information:

DOI: https://doi.org/10.1111/ijd.15999

Keywords: azoles, onychomycosis, dermatomycoses, posaconazole, fosravuconazole, voriconazole, oteseconazole, superficial fungal infection, Antifungal resistance, Cure rate, mycological cure, alternative antifungal therapy, International Journal of Dermatology.